Plate Nº 11 · recorded October 10, 2026
Health & Medicine ResearchReported finding
MSK Reports Early Promise for KRAS-Targeted Pancreatic Cancer Therapy
Memorial Sloan Kettering has announced a new KRAS-targeted therapy showing early promise against pancreatic cancer, though the center has not yet released detailed efficacy data on the approach.
By James Calloway3 min read624 words
In brief
- Memorial Sloan Kettering announced a new KRAS-targeted therapy showing early promise against pancreatic cancer.
- KRAS mutations drive roughly 90% of pancreatic ductal adenocarcinomas, the most common form of the disease.
- Scientists first linked KRAS to human cancer in 1982; the FDA approved the first KRAS inhibitor, sotorasib, in 2021.
- Pancreatic cancer carries a five-year survival rate of roughly 13%.
- G12C accounts for only 1-2% of pancreatic KRAS cases, pushing most drug development toward the more common G12D variant.
Roughly 90% of pancreatic cancers carry a KRAS mutation, and Memorial Sloan Kettering Cancer Center has now joined a small group of institutions racing to drug that mutation, announcing a new KRAS-targeted therapy showing early promise against the disease.
The brief MSK news item, headlined "New KRAS Targeted Therapy Shows Promise Against Pancreatic Cancer," does not name the compound, specify which KRAS allele it targets, or report any efficacy figures.
Without those details, oncologists treating patients today have little actionable information. The announcement nonetheless marks another step in a research arc that has accelerated sharply since 2021.
Why has KRAS been so hard to drug?
Scientists first identified KRAS mutations in human tumors in 1982. For nearly four decades, the protein's smooth surface offered almost no pocket for a small molecule to grip, earning it the label "undruggable."
G12D is the dominant KRAS allele in pancreatic cancer, appearing in roughly 40% of KRAS-mutant pancreatic tumors. The field began shifting in 2021 when the FDA approved sotorasib, the first KRAS G12C inhibitor, for non-small cell lung cancer.
G12C accounts for only about 1-2% of pancreatic KRAS cases. Drugmakers have since pivoted toward G12D and pan-KRAS approaches, several of which are now in early clinical trials.
Pancreatic tumors present an additional challenge. Dense stromal tissue surrounds them, limiting how much drug actually reaches cancer cells. That biology helps explain why KRAS inhibitors that work in lung cancer have so far struggled in pancreatic disease.
What does the MSK announcement say — and not say?
The MSK communication is short. It describes a "new KRAS targeted therapy" that "shows promise against pancreatic cancer." It does not specify whether the work is preclinical or clinical, the response rate, or any toxicity data.
Press releases in oncology routinely precede formal publication by months. Oncologists typically treat them as research signals rather than practice-changing news.
What does "promise" usually mean in early cancer research?
Researchers describe meaningful early signals in concrete terms: tumor shrinkage on imaging, drops in circulating tumor DNA, prolonged survival in mouse models, or partial responses in a small group of patients. Each of those markers has disappointed investigators before.
Independent replication in larger cohorts and peer review remain the field's standard gatekeepers. Patients and clinicians should wait for those before drawing conclusions about any new agent.
Where does MSK fit in the broader KRAS race?
Memorial Sloan Kettering has been among the most active academic centers in pan-KRAS drug discovery. Its researchers have published on G12D inhibitors, KRAS degraders, and combination strategies pairing KRAS blockade with other targeted agents.
The new announcement arrives against a backdrop of competing efforts from biotech firms such as Mirati Therapeutics, Revolution Medicines, and Erasca. Each is targeting various KRAS alleles in pancreatic and colorectal cancers.
A successful pancreatic KRAS therapy would likely pair a KRAS inhibitor with another drug — chemotherapy, immunotherapy, or a second targeted agent — to overcome resistance that monotherapies have so far failed to beat.
What milestones should readers watch for?
Three milestones would move the announcement from a research signal toward a real option for patients: peer-reviewed publication of preclinical or early clinical data, presentation at a major oncology meeting such as ASCO or AACR, and the launch of a phase 1 trial.
Until one of those appears, the work remains in the realm of early-stage science.
For patients with pancreatic cancer now, the practical pathway has not changed: surgery when feasible, standard combination chemotherapy such as FOLFIRINOX or gemcitabine plus nab-paclitaxel, and — for eligible patients — enrollment in a clinical trial. Researchers will judge the new MSK work, like its competitors, by whether it can extend survival beyond the current five-year rate of roughly 13%.
via Google News: Clinical Trials (Source)
More from James Calloway
Show full bio
Staff writer covering marketplaces and e-commerce at SciBeat.
205 articles